Pfizer and Sanofi-Aventis Statement on Status of Exubera


Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said that the U.S. food and Drug Administration has notified the companies that it is extending its original review period for Exubera® (insulin [rDNA origin] powder for oral inhalation) by three months to review additional technical chemistry data submitted by the companies.

In September, an FDA Advisory Committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. FDA is not obligated to follow the Advisory Committee's recommendation, but usually does so. Pfizer and sanofi-aventis continue to work closely with the FDA so that this important medicine can be made available for patients.

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!